ERBB3 and non-small cell lung carcinoma: To assess the impact of HRG-ERBB2-ERBB3 and HRG-EGFR-ERBB3 signalling axis on cell viability and proliferation in EML4-ALK-harbouring NSCLC cells, we treated H3122 and H2228 cells with either ERL, SAP alone or in combination with LOR in the presence of HRG ligand (Fig. 5A, F).